3,3-Difluoroazetidine hydrochloride → HCID 90214928, 화합물
반응식
[CH:1]1([C:4]2[C:5]([O:21][CH2:22][C:23]([F:26])([F:25])[F:24])=[CH:6][C:7]([C:10]([NH:12][CH:13]([C:17]([CH3:20])([CH3:19])[CH3:18])[C:14](O)=[O:15])=[O:11])=[N:8][CH:9]=2)[CH2:3][CH2:2]1.Cl.[F:28][C:29]1([F:33])[CH2:32][NH:31][CH2:30]1>>[CH:1]1([C:4]2[C:5]([O:21][CH2:22][C:23]([F:25])([F:26])[F:24])=[CH:6][C:7]([C:10]([NH:12][CH:13]([C:17]([CH3:18])([CH3:20])[CH3:19])[C:14]([N:31]3[CH2:32][C:29]([F:33])([F:28])[CH2:30]3)=[O:15])=[O:11])=[N:8][CH:9]=2)[CH2:2][CH2:3]1참가 물질
3
실험 절차
The title compound was synthesized in analogy to Example 112e, using 2-[[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridine-2-carbonyl]amino]-3,3-dimethyl-butanoic acid (Example 194b) and 3,3-Difluoroazetidine hydrochloride (CAN 288315-03-7) as starting materials and isolated (31 mg, 53%); MS (ESI, m/z): 450.5 (M+H+).
후처리
- customisolated (31 mg, 53%)
출처 및 근거
- ORD 기록